Brand Insights - Thought Leadership | Paid Program
Issei Tsukamoto, SVP, Head of Business Development, Astellas Pharma Inc.
Advertisement
Articles by Issei Tsukamoto, SVP, Head of Business Development, Astellas Pharma Inc.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5